Isis Pharmaceuticals, Inc., a bio-pharmaceutical company, specializes in anti-sense technology using a novel drug discovery platform to generate a broad pipeline of first-in-class drugs. The company led the industry in the development of RNA-targeted technologies to change the way diseases are treated.
Antisense technology focuses on treating genetic disorders or infections, providing a direct route from genomics to drugs. With the drug discovery platform of Isis, their strategy is to discover more unique antisense drugs and develop them to address significant medical needs.
Its flagship product includes the KYNAMRO (mipomersen sodium) injection for patients with homozygous familial hypercholesterolemia, or HoFH. It also has a pipeline of 32 drugs that focus on the treatment of many different diseases, with an emphasis on cardiovascular and metabolic diseases; severe and rare diseases, which include inflammatory and neurodegenerative; and cancer. Apart from its drug discovery, they also generated a substantial portfolio of scientific publications.
Isis has solid alliances and collaboration deals primarily with Biogen Idec, Genzyme, GlaxoSmithKline, AstraZeneca and Roche. They conduct early development of new drugs and out license them to their partners.
As a leader and innovator in antisense drug discovery, they have implemented a patent strategy that has provided them with strong protection for its drugs and technology. Isis continues making improvements in their drug discovery platform to expand the scientific understanding of antisense technology.
|Services||Antisense Drug Discovery Platform|
|Phone||13-02-6555049 | 760-931-9200|
|Address||2855 Gazelle Court Carlsbad, CA 92010 United States of America|